Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Dose-escalation Study of BAY1129980

Complete title: An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Research Study Number 20161858
Principal Investigator Rafael Santana-Davila
Phase I

Research Study Description

The purpose of this study is to evaluate:

- The side effects of BAY1129980 when given every 21 days different dose levels.

- Determine the dose level of BAY1129980 that should be tested in future clinical research studies.

- Measure how much BAY1129980 is in the blood at specific times after administration.

- If treatment with BAY1129980 shows any effect on reducing the tumor growth.

- If there are specific biomarkers that might be able to explain why some patients respond to treatment and others do not.

- If treatment with BAY1129980 causes an immune response from the body against the drug (immunogenicity).

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20161858
Contact Seattle Cancer Care Alliance Intake Office
Telephone 800-804-8824 / 206-606-1024

Keywords: Bladder Cancer; Breast Cancer; Esophageal Cancer; Gastrointestinal Cancer; Gynecological Cancer; Lung Cancer; Solid Tumors; Neoplasms; Immunotherapy; Esophageal Diseases; Gastrointestinal Diseases

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials